MitchellSCairoMD

Pediatric Hematology & Oncology • Hawthorne, NY

Pediatric Solid Tumor Oncology

Professor of Pediatrics, New York Medical College

Join to view full profile

Dr. Cairo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cairo's full profile

Already have an account?

Office
19 Bradhurst Ave
Suite 800
Hawthorne, NY 10532
Phone+1 914-594-3650

Fax+1 914-594-3803

Education & Training

Indiana University School of MedicineFellowship, Pediatric Hematology/Oncology, 1979 - 1981
Los Angeles County-Harbor-UCLA Medical CenterResidency, Pediatrics, 1976 - 1978
University of California San Francisco School of MedicineClass of 1976

Certifications & Licensure

CA State Medical License 1977 - 2026
NY State Medical License 2000 - 2025
FL State Medical License 2021 - 2023
DC State Medical License 1998 - 2004
IN State Medical License 1979 - 1982
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2003-2014
America's Top Doctors Castle Connolly, 2002-2014
Westchester Magazine: Top Doctors Castle Connolly, 2012-2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2009, 2012-2013
Join now to see all

Clinical Trials

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Start of enrollment: 2001 Jun 01
Completed
Phase 3
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Start of enrollment: 1998 Nov 01
Completed
Phase 1
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma Start of enrollment: 2002 Jun 01
Terminated
Phase 1
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Start of enrollment: 2004 Jun 01
Completed
Phase 2
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2005 Feb 01
Completed
Phase 1, Phase 2
Treatment of Mature B-cell Lymphoma/Leukaemia Start of enrollment: 1996 May 01
Completed
Phase 3
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML Start of enrollment: 2004 May 01
Terminated
Phase 1
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) Start of enrollment: 2007 Aug 01
Terminated
Phase 1
Denileukine Diftitox for Relapsed ALCL Start of enrollment: 2008 Dec 01
Withdrawn
Phase 2
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Start of enrollment: 2011 Sep 01
Completed
Phase 2
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders Start of enrollment: 2002 Nov 01
Terminated
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease Start of enrollment: 2012 Jan 01
Active, not recruiting
Phase 2
Human Placental-Derived Stem Cell Transplantation Start of enrollment: 2013 Apr 01
Completed
Phase 1
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma Start of enrollment: 2013 Jan 01
Terminated
Phase 2
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Start of enrollment: 2013 Aug 01
Completed
Phase 3
Treatment for Advanced B-Cell Lymphoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma Start of enrollment: 2014 Jan 01
Completed
Phase 1
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
SCT Plus Immune Therapy in Average Risk AML/MDS Start of enrollment: 2012 Jan 12
Completed
Phase 2
ODSH + ICE Chemotherapy in Pediatric Solid Tumors Start of enrollment: 2015 Jan 01
Terminated
Phase 1
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS Start of enrollment: 2011 Dec 07
Completed
Phase 2
Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy Start of enrollment: 2019 Dec 01
Withdrawn
Phase 2
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease Start of enrollment: 2017 Jul 01
Recruiting
Phase 2
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Start of enrollment: 2018 Nov 01
Recruiting
Phase 2
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) Start of enrollment: 2018 Nov 01
Recruiting
Phase 2
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection Start of enrollment: 2020 Jul 07
Recruiting
Phase 2
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome Start of enrollment: 2018 Jan 12
Completed
Phase 2
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion Start of enrollment: 2021 Apr 01
Recruiting
Phase 2
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) Start of enrollment: 2020 Jul 01
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease Start of enrollment: 2021 Sep 20
Recruiting
Phase 1, Phase 2
Roles: Contact, Study Chair
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma Start of enrollment: 2022 Feb 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Defibrotide in Children With High Risk Kawasaki Disease Start of enrollment: 2021 Feb 24
Active, not recruiting
Phase 2
Roles: Contact
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Start of enrollment: 2015 Aug 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Study Chair
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Start of enrollment: 2019 Mar 01
Recruiting
Early Phase 1
Roles: Principal Investigator, Study Director, Contact
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma Start of enrollment: 2023 May 22
Recruiting
Phase 1
Roles: Contact, Study Chair
Defibrotide Dose-escalation for SOS Post-HSCT Start of enrollment: 2024 Mar 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
CMV CTLs in Neonates With CMV Infection Start of enrollment: 2023 Jul 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.
Wen Luo, Hai Hoang, Hongwen Zhu, Katherine Miller, Xiaokui Mo
Journal for Immunotherapy of Cancer. 2024-09-12
binding domain mutations are bad news in Burkitt lymphoma.
Mitchell S Cairo
Haematologica. 2024-09-01
1 citations
Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
Wen Luo, Hai Hoang, Katherine E Miller, Hongwen Zhu, Serena Xu
Journal of Experimental & Clinical Cancer Research. 2024-07-11

Journal Articles

Overall Survival of Children and Adolescents with Mature B Cell Non‐Hodgkin Lymphoma Who Had Refractory or Relapsed Disease During or After Treatment with FAB/LMB 96: ...
Mitchell Cairo, Sherrie L Perkins, Stanton Goldman, British Journal of Haematology
The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...
Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature

Abstracts/Posters

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents
Mitchell S Cairo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
Mitchell S Cairo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Youn...
Mitchell S Cairo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Pa...
Mitchell S Cairo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cord Blood‐Derived Stem Cells Suppress Fibrosis and May Prevent Malignant Progression in Recessive Dystrophic Epidermolysis Bullosa
Mitchell Cairo, MD, Stem Cells, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Cord Blood Banking for Potential Future TransplantationOctober 2017

Press Mentions

Dribble for the Cure -St. John’s 2019September 21st, 2018

Grant Support

Ph2 Of T-Cell Depl Familial Haploidentical SCT For Tx Hi-Risk Sickle Cell AnemiaFood And Drug Administration2012
First Int'L Symposium On Childhood And Adolescent NHLNational Cancer Institute2003
Nonablative Allosct In Refractory Autoimmune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002–2003
Transplant Center For Umbilical Cord Stem CellDivision Of Blood Diseases And Resources1996–1998
Collection And Storage Center For Clinical ResearchDivision Of Blood Diseases And Resources1996–1998